Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07549646Phase 2Active Not Recruiting

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Role: collaborator

NCT07543822Phase 2Active Not Recruiting

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

Role: collaborator

NCT05543993Completed

COVID Booster in Pregnancy and Lactation

Role: collaborator

All 3 trials loaded